The $34.5M deal is a modest but positive step for Emergent's contract manufacturing business, leveraging the Canton facility's clean regulatory status. However, the vaccine is not yet FDA-approved, and U.S. government distribution revenue is contingent on that approval. Monitor for FDA submission progress and any additional manufacturing partnerships that could further utilize Canton capacity.
Price Chart
Executive Summary
Emergent BioSolutions announced a ~$34.5M agreement with Substipharm Biologics to manufacture drug substance for the IMOJEV Japanese Encephalitis vaccine at its Canton, MA facility and to serve as exclusive U.S. government distributor upon FDA approval. The deal leverages Emergent's recently cleared Canton facility (FDA 'No Action Indicated' status) and provides a new revenue stream, but the vaccine is not yet FDA-approved and the total value is modest relative to EBS's $415M market cap.
Key Financial Metrics
Key Facts
- Agreement valued at approximately $34.5 million.
- Emergent will manufacture IMOJEV drug substance at its Canton, MA facility.
- Emergent will be exclusive distributor of IMOJEV to the U.S. government upon FDA approval.
- Canton facility received FDA 'No Action Indicated' status after February 2026 inspection.
- IMOJEV is not yet approved for use in the U.S.; regulatory submission to FDA is pending.
- Emergent plans to hire additional employees at Canton facility later this year.
- Substipharm acquired IMOJEV in 2022; vaccine has been used in Asia since 2012.
Financial Impact
~$34.5 million total agreement value, with manufacturing and potential distribution revenue contingent on FDA approval.
Risk Factors
- IMOJEV is not FDA-approved; regulatory timeline and approval are uncertain.
- U.S. government distribution revenue is contingent on FDA approval and may take years to materialize.
- The $34.5M deal value is small relative to Emergent's $415M market cap, limiting near-term financial impact.
- Emergent's historical performance on prior reports shows negative T+20 alpha, suggesting market skepticism toward company announcements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282615 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $4.45 $5.68 | ▼ −27.64% | ▼ −28.70% | $6.29 (−41.35%) |
Jun 29, 2026 13w ago | 8-K | $8.46 $7.26 | ▼ −14.18% | ▼ −13.90% | $6.29 (−25.65%) |
Jun 4, 2026 17w ago | Press Release | $8.44 $8.28 | ▼ −1.90% | ▼ −0.52% | $6.29 (−25.47%) |
Apr 30, 2026 22w ago | Press Release | $8.47 $8.49 | ▲ +0.24% | ▼ −5.05% | $6.29 (−25.74%) |
Apr 30, 2026 22w ago | Insider Cluster | $8.23 $9.18 | ▲ +11.54% | ▲ +6.58% | $6.29 (−23.57%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 28, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 28, 2026 22w ago | Press Release | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 27, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access